Royalty Report: Drugs, Pharmaceuticals, Addiction – Collection: 7531

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 8

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Addiction
  • Therapeutic
  • Medical
  • Disease
  • Delivery
  • Technical Know How
  • Cancer
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7531

License Grant
The Licensor shall grant to the Licensee an exclusive License for the territory consisting of the forty-eight most northern counties of the state of California, to use and distribute the Counseling Programs and certain products, including the Naltrexone Implant.
License Property
The Licensor provides an innovative alcohol treatment program that empowers patients to succeed in their overall recovery. We offer a unique treatment philosophy that combines medical intervention, a singular focus and a comprehensive approach, and a focus on family and friends.

The Licensor has developed and owns worldwide rights to the Fresh Start Private Alcohol.

The Naltrexone implant is a special formulation of Naltrexone, which is designed to release slowly over a 6-12 week period. It is placed under the patient's skin and so it is effective and does not allow the patient to forget or skip their medicine.

Naltrexone is a pure narcotic antagonist. It attaches to the endorphin or opiate receptors in the brain and completely blocks them. This means that if someone tries to use any kind of opiate while they are on Naltrexone, they feel no effect because all of the receptors are completely blocked. While Naltrexone is in the body, it is virtually impossible to relapse.

Field of Use
The Field of Use is an alcohol treatment program.

IPSCIO Record ID: 4464

License Grant
The Company shall grant the Licensee, for the territory, an exclusive License to use and distribute the Counseling Programs and certain products, including the Naltrexone Implant, constituting theLicensor Private Alcohol Rehabilitation Program.
License Property
The Licensor is involved in establishing alcohol rehabilitation and treatment center and has created certain alcohol therapeutic and rehabilitation programs (the Counseling Programs) consisting of a Naltrexone implant that is placed under the skin in the lower abdomen coupled with life counseling sessions from specialized counselors.

The Licensor has developed and owns worldwide rights to the Fresh Start Private Alcohol.

The Naltrexone implant is a special formulation of Naltrexone, which is designed to release slowly over a 6-12 week period. It is placed under the patient's skin and so it is effective and does not allow the patient to forget or skip their medicine.

Naltrexone is a pure narcotic antagonist. It attaches to the endorphin or opiate receptors in the brain and completely blocks them. This means that if someone tries to use any kind of opiate while they are on Naltrexone, they feel no effect because all of the receptors are completely blocked. While Naltrexone is in the body, it is virtually impossible to relapse.

Field of Use
The Field of Use is certain alcohol therapeutic and rehabilitation programs.

IPSCIO Record ID: 7358

License Grant
In accordance with the terms and provisions of the License Agreement: the Licensor shall grant to the Licensee the exclusive rights to the License to use, sell and offer for sale in the State of Arizona the Naltrexone implant and includes the copyrighted, trademarked or patented materials inclusive of name, logo and other Licensor materials, such as advertising, marketing, publicity, public relations and publications.
License Property
The Licensed Property provides an innovative alcohol treatment program that empowers patients to succeed in their overall recovery, offering a unique treatment philosophy that combines medical intervention, a singular focus and a comprehensive approach, and a focus on family and friends.

The Naltrexone implant is a special formulation of Naltrexone, which is designed to release slowly over a 6-12 week period. It is placed under the patient's skin and so it is effective and does not allow the patient to forget or skip their medicine.

Naltrexone is a pure narcotic antagonist. It attaches to the endorphin or opiate receptors in the brain and completely blocks them. This means that if someone tries to use any kind of opiate while they are on Naltrexone, they feel no effect because all of the receptors are completely blocked. While Naltrexone is in the body, it is virtually impossible to relapse.

Field of Use
The rights granted is for the purpose of receiving, implanting, using, selling and otherwise importing for commercializing the Naltrexone implant.

IPSCIO Record ID: 7440

License Grant
Licensor hereby grants to the Licensee an exclusive license to use the Licensed Product, any procedures related to the licensed product.

Licensor has the exclusive license for Naltrexone Implant Product one which has been designed for Alcoholism.

License Property
Naltrexone is a pure narcotic antagonist. It attaches to the endorphin or opiate receptors in the brain and completely blocks them. This means that if someone tries to use any kind of opiate while they are on Naltrexone, they feel no effect because all of the receptors are completely blocked. While Naltrexone is in the body, it is virtually impossible to relapse.

The Naltrexone implant is a special formulation of Naltrexone, which is designed to release slowly over a 6-12 week period. It is placed under the patient's skin and so it is effective and does not allow the patient to forget or skip their medicine.

IPSCIO Record ID: 7439

License Grant
Licensor hereby grants to Licensee an exclusive sub-license in the License Territory to obtain, market, use, sell, and offer for sale, the Implants pursuant to the terms contained herein.

Trinity has granted to Licensor exclusive, worldwide licensing rights except for Australia and New Zealand  pursuant to that certain License Agreement entered into between Licensor and Trinity dated October 28, 2010 for Naltrexone Implants that have been designed to treat alcoholism.

Licensor has developed and owns worldwide rights to the Licensor Alcohol Rehabilitation Program.

Licensee desires to sub-license from Licensor the Licensor Rights solely for use in the License Territory (as defined below), upon the terms and conditions provided herein.

License Property
The Naltrexone implant is a special formulation of Naltrexone, which is designed to release slowly over a 6-12 week period. It is placed under the patient's skin and so it is effective and does not allow the patient to forget or skip their medicine.
Field of Use
Naltrexone is a pure narcotic antagonist. It attaches to the endorphin or opiate receptors in the brain and completely blocks them. This means that if someone tries to use any kind of opiate while they are on Naltrexone, they feel no effect because all of the receptors are completely blocked. While Naltrexone is in the body, it is virtually impossible to relapse.

IPSCIO Record ID: 96463

License Grant
The Irish Licensor granted an exclusive license to utilize the Technology in developing injectable naltrexone products to treat patients suffering addiction to opioids, methamphetamines, cocaine, or alcohol.  The grant permits the Licensee to sell the products that utilize the Technology.
License Property
The licensor has know-how and patents related to sustained release drug delivery technology.
Field of Use
Licensee distributes and licenses a recovery program for alcoholism and opioid addiction treatment that empowers patients to succeed in their overall recovery.

IPSCIO Record ID: 4361

License Grant
Licensor hereby grants to Licensee an exclusive worldwide license, with the right to grant sublicensed, in all fields under the Licensed patents, to make, have made, use, sell, offer for sale and import Licensed Products and to use Licensed Products.
License Property
Licensor is the owner by assignment of certain intellectual property relating to the treatment with opioid antagonists (such as naltrexone) and (met-enkephalin), alone or in combination with standard of care treatments, of a variety of diseases and conditions, including multiple sclerosis, cancer of the prostate, Lymphoproliferative syndrome, including such diseases as malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, is treated in human patients by the administration, chronic herpes virus infections, chronic herpes viral infections, including chronic genital herpes caused by the herpes simplex virus, Type 2, and chronic infections due to the Epstein-Barr virus, chronic, A treatment method for humans infected with HTLV-III (AIDS) virus, including patients clinically diagnosed as suffering from AIDS, those suffering from AIDS-related complex (ARC).  In particular, the inventions relate to methods and formulations for treatment of these conditions, including but not limited to all INDs, communications with regulatory agencies, patient data, and letters relating to the intellectual property.

The Intellectual Property relates to treatments with opioid antagonists such as naltrexone and et-enkephalin for a variety of diseases and conditions including malignant lymphoma, chronic lymphocytic leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma, chronic herpes virus infections, chronic herpes viral infections such as chronic genital herpes caused by the herpes simplex virus Type 2 and chronic infections due to the Epstein-Barr virus and a treatment method for humans infected with HTLV-III (AIDS) virus including patients clinically diagnosed as suffering from AIDS and those suffering from AIDS-related complex (ARC).

Licensed Patents:
U.S. Patent Number 6,586,443
U.S. Patent Number 6,384,044
U.S. Patent Number 6,288,074
U.S. Patent Number 5,356,900
U.S. Patent Number 5,013,739
U.S. Patent Number 4,888,346

Field of Use
The Licensee's most advanced clinical programs involve immunotherapy using Met-enkephalin (“MENK”) and low dose naltrexone (“LDN”). Both immunotherapies work by triggering opioid receptors on immune cells leading to an activation and expansion of various cells of the immune system.

In clinical trials, MENK has been shown to reduce early AIDS and AIDS Related Complex, a condition also known as pre-AIDS which include symptoms such as fever, diarrhea, weight loss, swollen lymph nodes and herpes.

IPSCIO Record ID: 2912

License Grant
The Licensor entered into a license and commercialization agreement with the Swiss Licensee to commercialize Vivitrol for the treatment of alcohol dependence and opioid dependence in Russia and other countries in the Commonwealth of Independent States.  Under the terms of the agreement, the Licensee has primary responsibility for securing all necessary regulatory approvals for Vivitrol and the Licensee's affiliate commercializes the product effective March 2009. The Licensor is responsible for the manufacture of Vivitrol and receives manufacturing and royalty revenues based upon product sales.  Vivitrol is the first and only once-monthly injectable medication for the treatment of alcohol dependence.
License Property
VIVITROL is an extended-release Medisorb formulation of naltrexone. VIVITROL is the first and only once-monthly injectable medication for the treatment of alcohol dependence. Alcohol dependence is a serious and chronic brain disease characterized by cravings for alcohol, loss of control over drinking, withdrawal symptoms and an increased tolerance for alcohol.
Field of Use
In August 2008, the Russian regulatory authorities approved Vivitrol for the treatment of alcohol dependence.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.